Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation
- 1 March 1992
- Vol. 10 (3) , 206-216
- https://doi.org/10.1002/syn.890100304
Abstract
Following 6‐hydroxydopamine (6‐OHDA) lesions of the nigrostriatal dopamine (DA) pathway, rat caudate‐putamen (CPu) neurons are supersensitive to the inhibitory effects of both D1 and D2 dopamine (DA) receptor selective agonists. In addition, both the necessity of D1 receptor stimulation for D2 agonist‐induced inhibition and the synergistic inhibitory effects of D1 and D2 agonists are abolished by denervation. The present study attempted to determine the relative roles of D1 and D2 DA receptors in the development of denervation supersensitivity to DA agonists and the “uncoupling” of functional interactions between the receptors following 6‐OHDA lesions of the nigrostriatal DA pathway. Beginning on the day after an intraventricular 6‐OHDA (or vehicle) injection, groups of rats received daily injections of either the selective D1 receptor agonist SKF 38393 (8.0 mg/kg, s.c.), the D2 agonist quinpirole (0.5 mg/kg, s.c.), or saline for 7 days. On the day following the last agonist injection, rats were anesthetized and prepared for extracellular single cell recording with iontophoretic drug administration. Daily administration of quinpirole selectively prevented the development of D2 receptor supersensitivity, whereas daily administration of SKF 38393 prevented the development of both D1 and D2 receptor supersensitivity. In addition, D1, but not D2, agonist treatment prevented the loss of synergistic inhibitory responses typically produced by 6‐OHDA lesions. Behavioral observations revealed similar effects; daily injections of SKF 38393, but not quinpirole, prevented contralateral rotational responses to the mixed D1/D2 agonist apomorphine (1.0 mg/kg, s.c.) in rats with unilateral 6‐OHDA lesions of the nigrostriatal pathway. After a 4‐week withdrawal from repeated D1 agonist treatment, both supersensitive inhibitory responses of CPu neurons and contralateral rotations to apomorphine were evident, indicating that the preventative effects on DA receptor supersensitivity were not permanent. These findings indicate that continued agonist occupation of striatal D1 DA receptors following DA denervation not only prevents the development of D1 DA receptor supersensitivity but also exerts a similar regulation of D2 receptor sensitivity.Keywords
This publication has 48 references indexed in Scilit:
- Turning off cortical ensembles stops striatal Up states and elicits phase perturbations in cortical and striatal slow oscillations in rat in vivoThe Journal of Physiology, 2006
- Relationship between D 1 dopamine receptors, adenylate cyclase, and the electrophysiological responses of rat nucleus accumbens neuronsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1991
- Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neurolepticsNature, 1990
- Haloperidol and clozapine: differential effects on the sensitivity of caudate-putamen neurons to dopamine agonists and cholecystokinin following one month continuous treatmentBrain Research, 1989
- D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systemsSynapse, 1989
- Striatal D1 dopamine receptor distribution following chemical lesion of the nigrostriatal pathwayBrain Research, 1988
- 6-Hydroxydopamine-induced degeneration of nigral dopamine neurons: Differential effect on nigral and striatal D-1 dopamine receptorsLife Sciences, 1987
- Hyperactivity induced by stimulation of separate dopamine D-1 and D-2 receptors in rats with bilateral 6-OHDA lesionsLife Sciences, 1985
- The effects of acute and chronic haloperidol treatment on spontaneously firing neurons in the caudate nucleus of the ratLife Sciences, 1979
- Dopaminergic denervation supersensitivity and dopamine stimulated adenyl cyclase activityNeuropharmacology, 1973